Videos and Podcasts

30th Nov 22

Pharmaxis Presents at Bell Potter Healthcare Conference 2022

Gary Phillips, Chief Executive Officer at Pharmaxis (ASX:PXS) presents at the Bell Potter Healthcare Conference on 9 November 2022.

Watch the presentation here.

19th Oct 22

PXS announces positive interim data from myelofibrosis trial

Pharmaxis Ltd (ASX: PXS) held an online investor briefing by chief executive officer Mr Gary Phillips on October 19 2022.

The event consisted of an analysis of data from patients who have completed 6 months’ treatment with PXS-5505 in its Phase 2 clinical trial in patients with the bone marrow cancer myelofibrosis. Followed by a Q&A session from attendees. You can watch a recording of the presentation here.

The presentation slides are available in full here.

26th Sep 22

Pharmaxis Releases Promising Interim Data from Skin Scarring Study

Pharmaxis has released promising  interim data from the clinical trial of its topical anti scarring drug PXS-6302 being conducted by the University of Western Australia (UWA) under the leadership of Professor Fiona Wood AM.  The study aims to improve the appearance and function of established scars by tackling the enzyme that plays a critical role in crosslinking collagen fibres in scar formation.

Watch an interview with CEO Gary Phillips outlining the study data here.

Watch the Channel Nine News story here

Watch the online investor briefing by chief executive officer Mr Gary Phillips on September 26 2022 here.